期刊
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
卷 94, 期 3, 页码 380-386出版社
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.13369
关键词
amyloidosis; cIg-FISH; t(11;14)
类别
资金
- Hematologic Malignancies Fund of the Mayo Clinic
- [CA062242]
Background Light chain amyloidosis is a rare plasma cell dyscrasia. Interphase fluorescence in situ hybridization (FISH) coupled to cytoplasmic staining of specific Ig (cIg-FISH) on bone marrow plasma cells has become well established in the initial evaluation of multiple myeloma, a related disorder. Little, however, is known about cytogenetic abnormalities in patients with light chain amyloidosis. Design and Methods We reviewed 56 patients with light chain amyloidosis who had cIg-FISH performed as part of their routine clinical testing using the standard screening panel employed in multiple myeloma at our institution. Results Seventy percent of patients had abnormal cIg-FISH, with the most common abnormalities being IgH translocations [48%] - including t(11,14) [39%], and t(14;16) [2%] - and del13/del13q [30%]. No t(4;14) or deletions of 17p (p53) were observed. Patients with t(11;14) had the lowest levels of clonal plasma cells, and those with del13 had the highest. The risk of death for patients harboring the t(11;14) translocation was 2.1 (CI 1.04-6.4); which on multivariate analysis was independent of therapy. Conclusions Although preliminary, our data would suggest that cIg-FISH testing is important in patients with light chain amyloidosis and that t(11;14) is an adverse prognostic factor in these patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据